Literature DB >> 1910436

Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients.

T F Schorn1, V Kliem, M Bojanovski, D Bojanovski, H Repp, H Bunzendahl, U Frei.   

Abstract

To determine the impact of long-term immunosuppression on serum lipids in stable renal graft recipients we measured serum lipids and apolipoprotein B concentrations in 20 patients receiving therapy with cyclosporin (CsA) and low-dose prednisolone (CsA/P) and in 18 patients on therapy with azathioprine and maintenance steroids (Aza/P). The patients were matched for age, body mass index, primary renal disease and dose of prednisolone, but not for the duration in transplantation and serum creatinine concentration. Triglyceride concentrations were significantly higher in the CsA/P group than in Aza/P-treated patients: 2.62 +/- 0.35 vs 1.62 +/- 0.23 mmol/l (P less than 0.05). Similarly, total cholesterol (C) levels were significantly more elevated in the CsA/P recipients than in the other group: 7.44 +/- 0.32 vs 5.84 +/- 0.25 (P less than 0.02). CsA/P patients had higher serum levels of LDL-C (4.79 +/- 0.20 vs 3.43 +/- 0.19 mmol/l (P less than 0.001) and apolipoprotein B concentrations (191 +/- 13 vs 128 +/- 9 mg/dl: P less than 0.001). CsA/P and Aza/P recipients had similar concentrations of HDL-C (1.73 +/- 0.13 vs 1.52 +/- 0.09 mmol/l: NS). We conclude that in stable renal graft recipients with good transplant function long-term immunosuppression with CsA/P is associated with a more atherogenic lipid status than therapy with Aza/P.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910436     DOI: 10.1007/bf00336404

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

3.  High-fat diets impede the lowering effect of cyclosporine A on rat brain lipids and interact with the expression of apolipoproteins E and J.

Authors:  Pascale Montpied; Nicole Domingo; Michèle Senft; Henri Portugal; Pierre Petit; Françoise Chanussot
Journal:  Lipids       Date:  2005-01       Impact factor: 1.880

Review 4.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

5.  Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.

Authors:  Mark D Pescovitz; Flavio Vincenti; Marquis Hart; Larry Melton; John Whelchel; Shamkant Mulgaonkar; Diane McKay; Mimi Leung; Elizabeth Calleja; M René Bouw
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

Review 6.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 7.  Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.

Authors:  Eric Thervet
Journal:  Int J Nanomedicine       Date:  2006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.